Event Details
Future (referenced as 'in the near future')
Description
FDA public meeting to gather stakeholder input on CBD products.
Participants (4)
| Name | Type | Mentions | |
|---|---|---|---|
| FDA | person | 0 | View Entity |
| Footwear manufacturers | person | 0 | View Entity |
| Consumers | person | 0 | View Entity |
| Scott Gottlieb | person | 4 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_024891.jpg
This document is a market research report from Cowen Washington Research Group dated February 25, 2019, authored by Assaraf and watermarked for Michael Cella. It analyzes the regulatory landscape for CBD following the passage of the 2018 Farm Bill, specifically highlighting that while hemp was declassified, the FDA (under Commissioner Scott Gottlieb) retains authority over CBD products making health claims or used in food. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was part of a document production for a Congressional investigation.
Related Events
Events with shared participants
FDA convened a meeting to analyze data on the drug Praluent, leading to its approval for a larger group of patients than expected.
Date unknown • U.S.
The FDA clearing the drug Praluent for patients with heterozygous familial hypercholesterolemia and certain types of heart disease.
Date unknown
Electricity prices increased by weighted average of close to 20%.
2016-01-01 • Saudi Arabia
FDA approval of Marinol and Cesamet
1985-01-01 • USA
Marinol approved for treatment of anorexia associated with AIDS
1992-01-01 • USA
Syndros approved by the FDA
2016-01-01 • USA
FDA gave green light for Geron clinical trial.
2009-01-01 • US
FDA accepted GW Pharmaceuticals’ New Drug Application (NDA) for the cannabis-derived drug Epidiolex.
2017-10-01 • USA
FDA published industry guidance on botanical drug development.
2016-12-01 • USA
Previous FDA guidance on botanical drugs issued.
2004-06-01 • USA
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event